How much did TBG Diagnostics achieve in EBIT for the current year?
In the current year, TBG Diagnostics has achieved an EBIT of 0 AUD.
TBG Diagnostics EBIT 2024
TBG Diagnostics EBIT
0 AUD
Ticker
TDL.AX
ISIN
AU000000TDL4
WKN
A2AD8F
In 2024, TBG Diagnostics's EBIT was 0 AUD, a 0% increase from the 0 AUD EBIT recorded in the previous year.
The TBG Diagnostics EBIT history
| YEAR | EBIT (undefined AUD) |
|---|---|
| 2025e | - |
| 2024e | - |
| 2023e | - |
| 2022e | - |
| 2021e | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
| 2005 | - |
| 2004 | - |
| 2003 | - |
| 2002 | - |
| 2001 | - |
TBG Diagnostics Revenue, EBIT, Net Income AU000000TDL4 · A2AD8F
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into TBG Diagnostics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by TBG Diagnostics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects TBG Diagnostics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of TBG Diagnostics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into TBG Diagnostics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing TBG Diagnostics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on TBG Diagnostics’s growth potential.
TBG Diagnostics Revenue, EBIT and net profit per share
| Date | TBG Diagnostics Revenue | TBG Diagnostics EBIT | TBG Diagnostics Net Income |
|---|---|---|---|
| 2025e | 213 M undefined | 0 undefined | 0 undefined |
| 2024e | 182.76 M undefined | 0 undefined | 0 undefined |
| 2023e | 156.76 M undefined | 0 undefined | 0 undefined |
| 2022e | 128.99 M undefined | 0 undefined | 0 undefined |
| 2021e | 112.7 M undefined | 0 undefined | 0 undefined |
| 2020 | 4.63 M undefined | -3.04 M undefined | -3.55 M undefined |
| 2019 | 3.44 M undefined | -2.05 M undefined | 764,940 undefined |
| 2018 | 3.24 M undefined | -2.64 M undefined | -4.15 M undefined |
| 2017 | 4.6 M undefined | -1.71 M undefined | -6.54 M undefined |
| 2016 | 1.39 M undefined | -2.81 M undefined | -2.62 M undefined |
| 2015 | 806,590 undefined | -1.86 M undefined | -1.86 M undefined |
| 2014 | 5.75 M undefined | -1.81 M undefined | -1.81 M undefined |
| 2013 | 3.51 M undefined | -2.81 M undefined | -2.09 M undefined |
| 2012 | 2.89 M undefined | -3.44 M undefined | -3.44 M undefined |
| 2011 | 3.67 M undefined | -6.05 M undefined | -6.1 M undefined |
| 2010 | 2.71 M undefined | -11.4 M undefined | -15.84 M undefined |
| 2009 | 4.94 M undefined | -12.29 M undefined | -5.47 M undefined |
| 2008 | 6.48 M undefined | -25.88 M undefined | -26.15 M undefined |
| 2007 | 3.78 M undefined | -20.66 M undefined | -22.45 M undefined |
| 2006 | 2.82 M undefined | -6.96 M undefined | -7.61 M undefined |
| 2005 | 3.11 M undefined | -5.92 M undefined | -5.94 M undefined |
| 2004 | 6.19 M undefined | -4.46 M undefined | -4.78 M undefined |
| 2003 | 8.16 M undefined | -3.75 M undefined | -7.58 M undefined |
| 2002 | 5.66 M undefined | -4.86 M undefined | -6.16 M undefined |
| 2001 | 3.55 M undefined | -6.32 M undefined | -1.15 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2001 | 3.55 M AUD | -6.32 M AUD | -1.15 M AUD |
| 2002 | 5.66 M AUD | -4.86 M AUD | -6.16 M AUD |
| 2003 | 8.16 M AUD | -3.75 M AUD | -7.58 M AUD |
| 2004 | 6.19 M AUD | -4.46 M AUD | -4.78 M AUD |
| 2005 | 3.11 M AUD | -5.92 M AUD | -5.94 M AUD |
| 2006 | 2.82 M AUD | -6.96 M AUD | -7.61 M AUD |
| 2007 | 3.78 M AUD | -20.66 M AUD | -22.45 M AUD |
| 2008 | 6.48 M AUD | -25.88 M AUD | -26.15 M AUD |
| 2009 | 4.94 M AUD | -12.29 M AUD | -5.47 M AUD |
| 2010 | 2.71 M AUD | -11.4 M AUD | -15.84 M AUD |
| 2011 | 3.67 M AUD | -6.05 M AUD | -6.1 M AUD |
| 2012 | 2.89 M AUD | -3.44 M AUD | -3.44 M AUD |
| 2013 | 3.51 M AUD | -2.81 M AUD | -2.09 M AUD |
| 2014 | 5.75 M AUD | -1.81 M AUD | -1.81 M AUD |
| 2015 | 806,590 AUD | -1.86 M AUD | -1.86 M AUD |
| 2016 | 1.39 M AUD | -2.81 M AUD | -2.62 M AUD |
| 2017 | 4.6 M AUD | -1.71 M AUD | -6.54 M AUD |
| 2018 | 3.24 M AUD | -2.64 M AUD | -4.15 M AUD |
| 2019 | 3.44 M AUD | -2.05 M AUD | 764,940 AUD |
| 2020 | 4.63 M AUD | -3.04 M AUD | -3.55 M AUD |
| 2021e | 112.7 M AUD | 0 AUD | 0 AUD |
| 2022e | 128.99 M AUD | 0 AUD | 0 AUD |
| 2023e | 156.76 M AUD | 0 AUD | 0 AUD |
| 2024e | 182.76 M AUD | 0 AUD | 0 AUD |
| 2025e | 213 M AUD | 0 AUD | 0 AUD |
TBG Diagnostics stock margins AU000000TDL4 · A2AD8F
The TBG Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TBG Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TBG Diagnostics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the TBG Diagnostics's sales revenue. A higher gross margin percentage indicates that the TBG Diagnostics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the TBG Diagnostics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the TBG Diagnostics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the TBG Diagnostics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the TBG Diagnostics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the TBG Diagnostics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
TBG Diagnostics Margin History
| TBG Diagnostics Gross margin | TBG Diagnostics Profit margin | TBG Diagnostics EBIT margin | TBG Diagnostics Profit margin |
|---|---|---|---|
| 2025e | 57.95 % | 0 % | 0 % |
| 2024e | 57.95 % | 0 % | 0 % |
| 2023e | 57.95 % | 0 % | 0 % |
| 2022e | 57.95 % | 0 % | 0 % |
| 2021e | 57.95 % | 0 % | 0 % |
| 2020 | 57.95 % | -65.6 % | -76.57 % |
| 2019 | 76.11 % | -59.51 % | 22.21 % |
| 2018 | 88.83 % | -81.65 % | -128.17 % |
| 2017 | 83.17 % | -37.23 % | -142.25 % |
| 2016 | 70.69 % | -201.63 % | -188.36 % |
| 2015 | 67.81 % | -230.55 % | -230.55 % |
| 2014 | 54.96 % | -31.48 % | -31.48 % |
| 2013 | 57.95 % | -80.06 % | -59.54 % |
| 2012 | 7.61 % | -119.03 % | -119.03 % |
| 2011 | 31.61 % | -164.85 % | -166.21 % |
| 2010 | 25.46 % | -420.66 % | -584.5 % |
| 2009 | 65.99 % | -248.79 % | -110.73 % |
| 2008 | 58.02 % | -399.38 % | -403.55 % |
| 2007 | 37.3 % | -546.56 % | -593.92 % |
| 2006 | 26.24 % | -246.81 % | -269.86 % |
| 2005 | 83.6 % | -190.35 % | -191 % |
| 2004 | 72.21 % | -72.05 % | -77.22 % |
| 2003 | 74.88 % | -45.96 % | -92.89 % |
| 2002 | 61.84 % | -85.87 % | -108.83 % |
| 2001 | 59.15 % | -178.03 % | -32.39 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2001 | 59.15 % | -178.03 % | -32.39 % |
| 2002 | 61.84 % | -85.87 % | -108.83 % |
| 2003 | 74.88 % | -45.96 % | -92.89 % |
| 2004 | 72.21 % | -72.05 % | -77.22 % |
| 2005 | 83.6 % | -190.35 % | -191 % |
| 2006 | 26.24 % | -246.81 % | -269.86 % |
| 2007 | 37.3 % | -546.56 % | -593.92 % |
| 2008 | 58.02 % | -399.38 % | -403.55 % |
| 2009 | 65.99 % | -248.79 % | -110.73 % |
| 2010 | 25.46 % | -420.66 % | -584.5 % |
| 2011 | 31.61 % | -164.85 % | -166.21 % |
| 2012 | 7.61 % | -119.03 % | -119.03 % |
| 2013 | 57.95 % | -80.06 % | -59.54 % |
| 2014 | 54.96 % | -31.48 % | -31.48 % |
| 2015 | 67.81 % | -230.55 % | -230.55 % |
| 2016 | 70.69 % | -201.63 % | -188.36 % |
| 2017 | 83.17 % | -37.23 % | -142.25 % |
| 2018 | 88.83 % | -81.65 % | -128.17 % |
| 2019 | 76.11 % | -59.51 % | 22.21 % |
| 2020 | 57.95 % | -65.6 % | -76.57 % |
| 2021e | 57.95 % | 0 % | 0 % |
| 2022e | 57.95 % | 0 % | 0 % |
| 2023e | 57.95 % | 0 % | 0 % |
| 2024e | 57.95 % | 0 % | 0 % |
| 2025e | 57.95 % | 0 % | 0 % |
TBG Diagnostics Aktienanalyse
What does TBG Diagnostics do?
TBG Diagnostics Ltd is an Australian company specializing in the manufacturing and marketing of in vitro diagnostic products. The company was originally founded in 2009 under the name TBG Biotechnology Pty Ltd and later became a corporation. The company's business model is to provide fast and reliable diagnostic solutions for various disease conditions. The company operates in various areas, including infectious diseases, diarrheal diseases, tumor diagnostics, cardiovascular diseases, and oncology. In the infectious diseases field, for example, TBG Diagnostics offers test kits for the diagnosis of HIV, hepatitis, dengue fever, and other infectious diseases. The test kits consist of immunological rapid tests that typically provide results within 15-20 minutes, allowing doctors to quickly make a diagnosis and initiate appropriate therapy. In the diarrheal diseases field, the company has developed a special test kit that allows for the detection of rotaviruses. Rotavirus infections are one of the most common causes of severe diarrhea in infants and can lead to serious complications if left untreated. TBG Diagnostics' tumor diagnostics division offers specialized test kits for the diagnosis of prostate cancer, breast cancer, and colorectal cancer. The test kits are based on the measurement of tumor markers in the blood and are a fast and non-invasive method for early cancer detection. The company's cardiovascular division offers test kits for the diagnosis of thyroid hormones and troponin. Troponin is a protein complex that is released into the blood in increased amounts when there is damage to the heart muscle and can be an indication of a heart attack. In collaboration with partners, TBG Diagnostics also develops innovative solutions for oncology. One example is a special test kit that enables personalized medicine for patients with advanced bladder cancer. The test kit analyzes the DNA of tumor cells and allows doctors to find individually tailored therapies for the patient. TBG Diagnostics is a successful company that has experienced steady growth in recent years. The company is listed on the Australian stock exchange and has a strong international distribution network, enabling it to distribute its products worldwide. Overall, TBG Diagnostics is a company specializing in the development and manufacturing of innovative diagnostic products. By focusing on various areas and collaborating with partners, the company can quickly respond to changing requirements in healthcare and offer customized solutions to its customers. TBG Diagnostics ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing TBG Diagnostics's EBIT
TBG Diagnostics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of TBG Diagnostics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
TBG Diagnostics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in TBG Diagnostics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about TBG Diagnostics stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company TBG Diagnostics.
How has the EBIT of TBG Diagnostics developed in recent years?
The EBIT of TBG Diagnostics has increased by 0% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company TBG Diagnostics?
The EBIT of TBG Diagnostics is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does TBG Diagnostics pay?
Over the past 12 months, TBG Diagnostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TBG Diagnostics is expected to pay a dividend of 0 AUD.
What is the dividend yield of TBG Diagnostics?
The current dividend yield of TBG Diagnostics is .
When does TBG Diagnostics pay dividends?
TBG Diagnostics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of TBG Diagnostics?
TBG Diagnostics paid dividends every year for the past 0 years.
What is the dividend of TBG Diagnostics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is TBG Diagnostics located?
TBG Diagnostics is assigned to the 'Health' sector.
Wann musste ich die Aktien von TBG Diagnostics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of TBG Diagnostics from 11/14/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/14/2024.
When did TBG Diagnostics pay the last dividend?
The last dividend was paid out on 11/14/2024.
What was the dividend of TBG Diagnostics in the year 2023?
In the year 2023, TBG Diagnostics distributed 0 AUD as dividends.
In which currency does TBG Diagnostics pay out the dividend?
The dividends of TBG Diagnostics are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von TBG Diagnostics
Our stock analysis for TBG Diagnostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TBG Diagnostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- TBG Diagnostics Revenue
- TBG Diagnostics Net Income
- TBG Diagnostics P/E
- TBG Diagnostics P/S
- TBG Diagnostics EBIT
- TBG Diagnostics Dividend
- TBG Diagnostics Stocks
- TBG Diagnostics Market capitalization
- TBG Diagnostics Debt
- TBG Diagnostics Liabilities
- TBG Diagnostics Equity
- TBG Diagnostics AAQS
- TBG Diagnostics Employees
- TBG Diagnostics ROE
- TBG Diagnostics ROA
- TBG Diagnostics ROCE
